1
,2
NURS 6630N-NURS 6630F-NURS 6630C:
Psychopharmacologic Approaches to Treatment of
Psychopathology
Questions 1–180 | Advanced Psychopharmacology for PMHNPs | | Graded
A+ questions with correct answers and rationale
1. A patient is started on fluoxetine (Prozac) for major depressive
disorder. The PMHNP understands that the therapeutic effect of SSRIs
is primarily due to which of the following mechanisms?
A. Blocking dopamine D2 receptors in the mesolimbic pathway
B. Inhibiting the reuptake of serotonin at the presynaptic neuron, increasing
serotonin availability in the synaptic cleft
C. Blocking acetylcholine esterase to increase cholinergic neurotransmission
D. Enhancing GABA-A receptor activity to produce calming effects
Answer: B
Explanation: SSRIs work by selectively blocking the serotonin transporter
(SERT) on the presynaptic neuron, preventing serotonin reuptake and
increasing its concentration in the synaptic cleft. This enhanced serotonergic
neurotransmission is responsible for their antidepressant, anxiolytic, and
anti-OCD effects. Option A describes the mechanism of first-generation
antipsychotics. Option C describes acetylcholine esterase inhibitors used for
Alzheimer's disease. Option D describes benzodiazepines and barbiturates.
,3
2. A PMHNP is educating a nursing student about the dopamine
hypothesis of schizophrenia. Which statement BEST explains the
current understanding of dopamine dysregulation in schizophrenia?
A. There is global dopamine excess throughout all brain regions
B. Hyperactivity of dopamine in the mesolimbic pathway causes positive
symptoms, while hypoactivity in the mesocortical pathway causes negative
and cognitive symptoms
C. Schizophrenia is caused solely by serotonin deficiency, not dopamine
dysregulation
D. Dopamine excess in the nigrostriatal pathway is responsible for both
positive and negative symptoms
Answer: B
Explanation: The dopamine hypothesis has evolved to recognize regional
specificity: mesolimbic dopamine hyperactivity (D2 receptor hypersensitivity)
is associated with positive symptoms such as hallucinations and delusions,
while mesocortical dopamine hypoactivity (D1 receptor hypofunction)
correlates with negative symptoms (blunted affect, alogia, avolition) and
cognitive impairments. The nigrostriatal pathway (dopamine deficiency) is
associated with extrapyramidal side effects from antipsychotics, not
symptom generation.
, 4
3. Which receptor mechanism best explains the weight gain commonly
observed with olanzapine (Zyprexa)?
A. Dopamine D2 receptor blockade in the striatum
B. Serotonin 5-HT2A receptor blockade in cortical regions
C. Histamine H1 receptor blockade combined with muscarinic M3 receptor
antagonism
D. Alpha-1 adrenergic receptor blockade causing fluid retention
Answer: C
Explanation: Olanzapine has high affinity for histamine H1 receptors
(causing sedation and appetite stimulation) and muscarinic M3 receptors on
pancreatic beta cells (impairing glucose-stimulated insulin secretion and
contributing to metabolic syndrome). Together, these mechanisms drive
significant weight gain and metabolic dysregulation. Dopamine D2 blockade
causes EPS. Serotonin 5-HT2A blockade improves negative symptoms and
reduces EPS risk. Alpha-1 blockade causes orthostatic hypotension.
4. The PMHNP is reviewing the pharmacodynamics of buspirone (Buspar)
with a patient. The mechanism of action that distinguishes buspirone
from benzodiazepines is:
A. Buspirone enhances GABA-A receptor chloride channel conductance
B. Buspirone is a partial agonist at serotonin 5-HT1A receptors and a weak
D2 receptor antagonist, with no activity at GABA receptors
,2
NURS 6630N-NURS 6630F-NURS 6630C:
Psychopharmacologic Approaches to Treatment of
Psychopathology
Questions 1–180 | Advanced Psychopharmacology for PMHNPs | | Graded
A+ questions with correct answers and rationale
1. A patient is started on fluoxetine (Prozac) for major depressive
disorder. The PMHNP understands that the therapeutic effect of SSRIs
is primarily due to which of the following mechanisms?
A. Blocking dopamine D2 receptors in the mesolimbic pathway
B. Inhibiting the reuptake of serotonin at the presynaptic neuron, increasing
serotonin availability in the synaptic cleft
C. Blocking acetylcholine esterase to increase cholinergic neurotransmission
D. Enhancing GABA-A receptor activity to produce calming effects
Answer: B
Explanation: SSRIs work by selectively blocking the serotonin transporter
(SERT) on the presynaptic neuron, preventing serotonin reuptake and
increasing its concentration in the synaptic cleft. This enhanced serotonergic
neurotransmission is responsible for their antidepressant, anxiolytic, and
anti-OCD effects. Option A describes the mechanism of first-generation
antipsychotics. Option C describes acetylcholine esterase inhibitors used for
Alzheimer's disease. Option D describes benzodiazepines and barbiturates.
,3
2. A PMHNP is educating a nursing student about the dopamine
hypothesis of schizophrenia. Which statement BEST explains the
current understanding of dopamine dysregulation in schizophrenia?
A. There is global dopamine excess throughout all brain regions
B. Hyperactivity of dopamine in the mesolimbic pathway causes positive
symptoms, while hypoactivity in the mesocortical pathway causes negative
and cognitive symptoms
C. Schizophrenia is caused solely by serotonin deficiency, not dopamine
dysregulation
D. Dopamine excess in the nigrostriatal pathway is responsible for both
positive and negative symptoms
Answer: B
Explanation: The dopamine hypothesis has evolved to recognize regional
specificity: mesolimbic dopamine hyperactivity (D2 receptor hypersensitivity)
is associated with positive symptoms such as hallucinations and delusions,
while mesocortical dopamine hypoactivity (D1 receptor hypofunction)
correlates with negative symptoms (blunted affect, alogia, avolition) and
cognitive impairments. The nigrostriatal pathway (dopamine deficiency) is
associated with extrapyramidal side effects from antipsychotics, not
symptom generation.
, 4
3. Which receptor mechanism best explains the weight gain commonly
observed with olanzapine (Zyprexa)?
A. Dopamine D2 receptor blockade in the striatum
B. Serotonin 5-HT2A receptor blockade in cortical regions
C. Histamine H1 receptor blockade combined with muscarinic M3 receptor
antagonism
D. Alpha-1 adrenergic receptor blockade causing fluid retention
Answer: C
Explanation: Olanzapine has high affinity for histamine H1 receptors
(causing sedation and appetite stimulation) and muscarinic M3 receptors on
pancreatic beta cells (impairing glucose-stimulated insulin secretion and
contributing to metabolic syndrome). Together, these mechanisms drive
significant weight gain and metabolic dysregulation. Dopamine D2 blockade
causes EPS. Serotonin 5-HT2A blockade improves negative symptoms and
reduces EPS risk. Alpha-1 blockade causes orthostatic hypotension.
4. The PMHNP is reviewing the pharmacodynamics of buspirone (Buspar)
with a patient. The mechanism of action that distinguishes buspirone
from benzodiazepines is:
A. Buspirone enhances GABA-A receptor chloride channel conductance
B. Buspirone is a partial agonist at serotonin 5-HT1A receptors and a weak
D2 receptor antagonist, with no activity at GABA receptors
